Future Sequencing Strategies for BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

In the concluding scientific discussion, Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla reflect on how emerging clinical evidence is shaping the future role of BCMA-directed therapies in relapsed/refractory multiple myeloma (RRMM).

The faculty discuss the increasingly encouraging outcomes observed with bispecific antibodies in earlier lines of therapy and how these data may influence future treatment algorithms.

Dr. Huff highlights several important unanswered questions, including the potential role of time-limited therapy, the impact of treatment sequencing on long-term outcomes, and how bispecific antibodies may be integrated alongside cellular therapies as clinical experience grows.

The panel also explores the importance of expanding access to advanced therapies across community and academic settings, noting that broader adoption may help more patients benefit from these treatment advances.

Ultimately, the discussion emphasizes that while BCMA-directed therapies are transforming RRMM management, optimizing sequencing strategies and improving access remain key priorities for the field moving forward.